Dr. Ryan J. Sullivan, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- University of Connecticut School of Medicine (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 221
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: University of Connecticut School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
MA license 222743
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- Newton-Wellesley Hospital Newton, MA
- Massachusetts Eye and Ear Infirmary - Boston, MA
- Nantucket Cottage Hospital Nantucket, MA
Medical groups
- Massachusetts General Physicians Organization Inc (3,558 clinicians)
- Brigham and Womens Physicians Organization Inc (2,994 clinicians)
- The General Hospital Corporation (1,267 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 221
- Services billed
- 559
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 280 | 115 |
| Established patient office or other outpatient visit, 30-39 minutes | 154 | 107 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 45 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Cambridge, MA | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $145 in total to this clinician.
| Immunocore Limited | $124 |
|---|---|
| Merck Sharp & Dohme LLC | $20.81 |
| Food and Beverage | $145 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 18 industry-funded studies in 2025, from 10 companies. The companies reported $1,260,266 in research payments for these studies, mostly to the institutions running them.
- Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM)
Immunocore Limited - Ph IA IB personalized cancer vaccine atezolizumabb
Genentech, Inc. - A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas
Novartis Pharmaceuticals Corporation - An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
ModernaTX, Inc. · Active, not recruiting · NCT03897881 - Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
ModernaTX, Inc. · Recruiting · NCT05533697 - Ph 2 Randomized POC Study of PCV in 1L Melanoma
Genentech, Inc. - A phase II trial of abbreviated MAPK targeted therapy plus pembrolizumab in patients with unresectable or metastatic melanoma
Merck Sharp & Dohme LLC - A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical study of Adjuvant V940 mRNA-4157 Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Sta…
Merck Sharp & Dohme LLC - MEKRAF-AST-101
Springworks Therapeutics, Inc. - Encorafenibbinimetinib master protocol an openlabel continuation study for participants continuing from encorafenibbinimetinib clinical studies
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.